Compare DKI & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DKI | GRDX |
|---|---|---|
| Founded | 2018 | N/A |
| Country | Hong Kong | United Kingdom |
| Employees | N/A | 2 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7M | 7.4M |
| IPO Year | N/A | N/A |
| Metric | DKI | GRDX |
|---|---|---|
| Price | $0.43 | $2.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 493.4K | 136.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $1.92 |
| 52 Week High | $11.80 | $5.30 |
| Indicator | DKI | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 47.67 | 43.21 |
| Support Level | $0.38 | $2.03 |
| Resistance Level | $0.47 | $3.65 |
| Average True Range (ATR) | 0.03 | 0.34 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 47.37 | 40.07 |
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.